Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

about

Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

Item

http://www.wikidata.org/entity/Q42700780

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Progesterone receptor membrane ...... atment in breast cancer cells.

@en

Progesterone receptor membrane ...... atment in breast cancer cells.

@nl

type

Item

label

Progesterone receptor membrane ...... atment in breast cancer cells.

@en

Progesterone receptor membrane ...... atment in breast cancer cells.

@nl

prefLabel

Progesterone receptor membrane ...... atment in breast cancer cells.

@en

Progesterone receptor membrane ...... atment in breast cancer cells.

@nl

P1476

Progesterone receptor membrane ...... atment in breast cancer cells.

@en

P2093

Alfred O Mueck

http://www.w3.org/2001/XMLSchema#string

Berthold Gierke

http://www.w3.org/2001/XMLSchema#string

Dieter Niederacher

http://www.w3.org/2001/XMLSchema#string

Gereon Poschmann

http://www.w3.org/2001/XMLSchema#string

Giuliano Bayer

http://www.w3.org/2001/XMLSchema#string

Hans Neubauer

http://www.w3.org/2001/XMLSchema#string

Harald Seeger

http://www.w3.org/2001/XMLSchema#string

Kai Stühler

http://www.w3.org/2001/XMLSchema#string

Marina Willibald

http://www.w3.org/2001/XMLSchema#string

Michael Pawlak

http://www.w3.org/2001/XMLSchema#string

P2860

Large-scale characterization of HeLa cell nuclear phosphoproteins

Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs

PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity!

Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2

Bioidentical hormone therapy

The retinoblastoma protein and cell cycle control

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

All progestins are not created equal

Estrogen receptor phosphorylation

Bioconversion of norethisterone, a progesterone receptor agonist into estrogen receptor agonists in osteoblastic cells

P304

72480-72493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19819

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29069804

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

5641147

http://www.w3.org/2001/XMLSchema#string